Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 ...

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million, to support Teva's anti-IL-15 candidate, TEV-'408 TE ...

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million, to support Teva’s anti-IL-15 candidate, ...

Ben Lloyd explores the key challenges of employing AI in manufacturing and highlights how new plug-and-play solutions are ...

Experts disagree on whether the vulnerabilities in a programmable logic controller from Delta are a five-alarm fire or not ...

Professional services company AON is expanding its insurance offering for datacentre developers and investors, citing the ...

Cognizant margins hold near 11% despite gross pressure from wage inflation and competition. Read here for a detailed analysis ...

We talked to experts in obesity, tobacco, artificial intelligence, HIV, TB and the NHI to find out what we can expect — and ...

Laughing Water Capital reported a 3.9% annual return, emphasizing fundamental growth in core holdings despite a market ...

Navan's Kim Hamer talks about what travel buyers say they need now, why the end-to-end experience matters, performance of AI ...

The MDF, supported by Department of Energy’s Advanced Materials and Manufacturing Technologies Office, is a nationwide ...

Sushi Casino is the best option for a live Irish casino, with a premium Live Dealer Selection from top studios – including ...